Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer

Detalles Bibliográficos
Autores principales: Kurozumi, Sasagu, Katayama, Ayaka, Shirabe, Ken, Horiguchi, Jun, Rakha, Emad A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555688/
https://www.ncbi.nlm.nih.gov/pubmed/34733421
http://dx.doi.org/10.18632/oncotarget.28007
_version_ 1784592028897640448
author Kurozumi, Sasagu
Katayama, Ayaka
Shirabe, Ken
Horiguchi, Jun
Rakha, Emad A.
author_facet Kurozumi, Sasagu
Katayama, Ayaka
Shirabe, Ken
Horiguchi, Jun
Rakha, Emad A.
author_sort Kurozumi, Sasagu
collection PubMed
description
format Online
Article
Text
id pubmed-8555688
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-85556882021-11-02 Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer Kurozumi, Sasagu Katayama, Ayaka Shirabe, Ken Horiguchi, Jun Rakha, Emad A. Oncotarget Editorial Impact Journals LLC 2021-10-26 /pmc/articles/PMC8555688/ /pubmed/34733421 http://dx.doi.org/10.18632/oncotarget.28007 Text en Copyright: © 2021 Kurozumi et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Editorial
Kurozumi, Sasagu
Katayama, Ayaka
Shirabe, Ken
Horiguchi, Jun
Rakha, Emad A.
Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer
title Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer
title_full Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer
title_fullStr Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer
title_full_unstemmed Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer
title_short Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer
title_sort clinicopathological utility of human epidermal growth factor receptor 2 (her2)-heterogeneity for next-generation treatments of triple-negative breast cancer
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555688/
https://www.ncbi.nlm.nih.gov/pubmed/34733421
http://dx.doi.org/10.18632/oncotarget.28007
work_keys_str_mv AT kurozumisasagu clinicopathologicalutilityofhumanepidermalgrowthfactorreceptor2her2heterogeneityfornextgenerationtreatmentsoftriplenegativebreastcancer
AT katayamaayaka clinicopathologicalutilityofhumanepidermalgrowthfactorreceptor2her2heterogeneityfornextgenerationtreatmentsoftriplenegativebreastcancer
AT shirabeken clinicopathologicalutilityofhumanepidermalgrowthfactorreceptor2her2heterogeneityfornextgenerationtreatmentsoftriplenegativebreastcancer
AT horiguchijun clinicopathologicalutilityofhumanepidermalgrowthfactorreceptor2her2heterogeneityfornextgenerationtreatmentsoftriplenegativebreastcancer
AT rakhaemada clinicopathologicalutilityofhumanepidermalgrowthfactorreceptor2her2heterogeneityfornextgenerationtreatmentsoftriplenegativebreastcancer

Ejemplares similares